UNSPSC 51142044: Xylazine hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H16N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NGC3S0882S, chemically known as 4h-1,3-thiazin-2-amine, n-(2,6-dimethylphenyl)-5,6-dihydro-, monohydrochloride, but more generally known as xylazine hydrochloride, which bears US NIH Compound Identifier 68554. European Medicines Agency schedules xylazine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00120MIG.

Most nations, for tariff purposes, schedule xylazine hydrochloride under HS 29349990. Xylazine hydrochloride bears US NLM identifiers UMLS ID C0242544 and NCI Concept Code C75050. SMILES: CC1CCCC(C1NC2=NCCCS2)C.CL.

UNSPSC 51142044 Xylazine hydrochloride is a Commodity code used by state and local health agencies to procure opioid antagonists, drug deactivation systems, and generic pharmaceuticals for public health and community safety initiatives. The scope encompasses naloxone procurement for overdose reversal, safe drug deactivation technologies, and generic multi-source pharmaceutical products distributed through state and local health departments and cooperative purchasing alliances. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing organizations. Seminole County, Florida (the issuing body in a recent IFB) and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the types of jurisdictions and cooperative vehicles soliciting under this code. The procurement mix reflects both direct commodity purchases by individual counties and statewide or multi-state framework agreements that coordinate pharmaceutical distribution across multiple participating jurisdictions.

Recent activity spans Florida, Minnesota, Oregon (through MMCAP participation), and Texas. Seminole County released IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, and a bid due date of July 26, 2023 (note: the posted date suggests a recurrence or reissuance of an earlier solicitation). MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with proposals due March 26, 2026, and contract effectiveness on July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Awards under the code are made on fixed-fee or competitive pricing bases with typical contract terms of two years and optional renewals, and vendors must comply with cGMP, the Drug Supply Chain Security Act, FDA requirements, and insurance thresholds.